Iranian Journal of Immunology

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Journal Metrics

SPIB Knockdown Inhibits the Immune Escape of Ovarian Cancer Cells by Reducing PD-L1 (CD274) Expression and Inactivating the JAK/STAT Pathway

Document Type : Original Article

Authors

Department of Gynecology, Binzhou Medical University Hospital, Binzhou, Shandong, 256600, China.

Abstract

Background: Spi-B transcription factor (SPIB) is an E-twenty-six (ETS) transcription factor associated with tumor immunity.
Objective: To investigate the functions and mechanisms of SPIB in ovarian cancer (OC) cells.
Methods: Cell proliferation, apoptosis, migration, and invasion were determined using colony formation, EdU, flow cytometry, and transwell assays, respectively. The binding sites of programmed death-ligand 1 (PD-L1) and SPIB were predicted using the JASPAR database and verified using the ChIP and luciferase reporter assays.
Results: SPIB knockdown inhibited OC cell proliferation, migration, and invasion, and significantly boosted apoptosis (p<0.05). SPIB directly enhanced PD-L1 transcription in OVCAR-3 and SKOV3 cells (p<0.05). Importantly, the JAK/STAT pathway was markedly inactivated in OC cells upon SPIB knockdown. SPIB knockdown markedly decreased JAK2 and STAT1 phosphorylation in OVCAR-3 and SKOV3 cells (p<0.05).
Conclusion: These data indicate that SPIB knockdown inhibits OC cell progression by downregulating PD-L1 and inactivating the JAK/STAT pathway.

Keywords

References
  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394-424
  2. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015; 385:977-1010
  3. Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. International journal of molecular sciences. 2019; 20
  4. Nero C, Vizzielli G, Lorusso D, Cesari E, Daniele G, Loverro M et al. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine. Journal of experimental & clinical cancer research : CR. 2021; 40:116
  5. Costa RM, Soto X, Chen Y, Zorn AM, Amaya E spib is required for primitive myeloid development in Xenopus. Blood. 2008; 112:2287-2296
  6. Ding M, Li Q, Tan X, Zhang L, Tan J, Zheng L Comprehensive pan-cancer analysis reveals the prognostic value and immunological role of SPIB. Aging. 2022; 14:6338-6357
  7. Ho YJ, Lin YM, Huang YC, Yeh KT, Lin LI, Lu JW Tissue microarray-based study of hepatocellular carcinoma validating SPIB as potential clinical prognostic marker. Acta histochemica. 2016; 118:38-45
  8. Wang J, Wang X, Guo Y, Ye L, Li D, Hu A et al. Therapeutic targeting of SPIB/SPI1-facilitated interplay of cancer cells and neutrophils inhibits aerobic glycolysis and cancer progression. Clinical and translational medicine. 2021; 11:e588
  9. Takagi Y, Shimada K, Shimada S, Sakamoto A, Naoe T, Nakamura S et al. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. Cancer science. 2016; 107:1270-1280
  10. Zhao X, Li L, Yuan S, Zhang Q, Jiang X, Luo T SPIB acts as a tumor suppressor by activating the NFkB and JNK signaling pathways through MAP4K1 in colorectal cancer cells. Cell Signal. 2021; 88:110148
  11. Montes-Moreno S, Ramos-Medina R, Martínez-López A, Barrionuevo Cornejo C, Parra Cubillos A, Quintana-Truyenque S et al. SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. Blood. 2013; 121:643-647
  12. Uppal S, Medlin E, Felder M, Kapur A, Sterner RC, Vazquez J et al. Identifying novel ovarian tumor biomarkers through mining of the transcriptome of circulating immune cells: A proof-of-concept study. American journal of reproductive immunology (New York, NY : 1989). 2021; 86:e13469
  13. Wang X, Teng F, Kong L, Yu J PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016; 9:5023-5039
  14. Shi X, Yun L, Chaoqun Liu L, Ding H, Liang D, Geng F et al. PD-L1 and the Clinical Outcomes of Ovarian Cancer: Meta-Analysis and Bioinformatical Analysis. Asian Pac J Cancer Prev. 2022; 23:2285-2290
  15. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016; 352:227-231
  16. Wu B, Song M, Dong Q, Xiang G, Li J, Ma X et al. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer. Theranostics. 2022; 12:5086-5102
  17. Hays E, Bonavida B YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resist Updat. 2019; 43:10-28
  18. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:20852-20857
  19. Chen X, He H, Xiao Y, Hasim A, Yuan J, Ye M et al. CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways. Frontiers in oncology. 2021; 11
  20. Nabeshima K, Inoue T, Shimao Y, Sameshima T Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int. 2002; 52:255-264
  21. James NE, Miller K, LaFranzo N, Lips E, Woodman M, Ou J et al. Immune Modeling Analysis Reveals Immunologic Signatures Associated With Improved Outcomes in High Grade Serous Ovarian Cancer. Frontiers in oncology. 2021; 11
  22. Huang Q, Liu J, Wu S, Zhang X, Xiao Z, Liu Z et al. Spi-B Promotes the Recruitment of Tumor-Associated Macrophages via Enhancing CCL4 Expression in Lung Cancer. Frontiers in oncology. 2021; 11:659131
  23. Jin J, Du X, Zhou L, Yao D, Zou Q SPI1-related protein inhibits cervical cancer cell progression and prevents macrophage cell migration. The journal of obstetrics and gynaecology research. 2022; 48:2419-2430
  24. Cojocaru E, Parkinson CA, Brenton JD Personalising Treatment for High-Grade Serous Ovarian Carcinoma. Clinical oncology (Royal College of Radiologists (Great Britain)). 2018; 30:515-524
  25. Peng H, He X, Wang Q Immune checkpoint blockades in gynecological cancers: A review of clinical trials. Acta obstetricia et gynecologica Scandinavica. 2022; 101:941-951
  26. Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. Journal of cellular physiology. 2019; 234:1313-1325
  27. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:3360-3365
  28. Baş Y, Koç N, Helvacı K, Koçak C, Akdeniz R, Şahin HHK Clinical and pathological significance of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer. Translational oncology. 2021; 14:100994
  29. Dumitru A, Dobrica EC, Croitoru A, Cretoiu SM, Gaspar BS Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer. International journal of molecular sciences. 2022; 23
  30. Cho MS, Lee H, Gonzalez-Delgado R, Li D, Sasano T, Carlos-Alcalde W et al. Platelets Increase the Expression of PD-L1 in Ovarian Cancer. Cancers. 2022; 14
  31. Lin J, Guo D, Liu H, Zhou W, Wang C, Müller I et al. The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity. Cancer immunology research. 2021; 9:1413-1424
  32. Zuo Y, Zheng W, Liu J, Tang Q, Wang SS, Yang XS MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells. Neoplasma. 2020; 67:93-101
  33. Wu F, Tian F, Qin C, Qin X, Zeng W, Liu X et al. Peroxiredoxin2 regulates trophoblast proliferation and migration through SPIB-HDAC2 pathway. Experimental cell research. 2023; 422:113428
  34. Zhang H, Wang G, Zhou R, Li X, Sun Y, Li Y et al. SPIB promotes anoikis resistance via elevated autolysosomal process in lung cancer cells. The FEBS journal. 2020; 287:4696-4709
  35. Carey P, Low E, Harper E, Stack MS Metalloproteinases in Ovarian Cancer. International journal of molecular sciences. 2021; 22
  36. Hira-Miyazawa M, Nakamura H, Hirai M, Kobayashi Y, Kitahara H, Bou-Gharios G et al. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage. International journal of oncology. 2018; 52:379-388
  37. Chen YL, Wang GX, Lin BA, Huang JS MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer. Cell Biol Int. 2020; 44:1224-1236
  38. Roshani Asl E, Rasmi Y, Baradaran B MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling. Journal of cellular physiology. 2021; 236:7071-7087
  39. Krafft U, Olah C, Reis H, Kesch C, Darr C, Grünwald V et al. High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy. Cancers. 2021; 13
  40. Ye Y, Kuang X, Xie Z, Liang L, Zhang Z, Zhang Y et al. Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1. Genome medicine. 2020; 12:83
  41. Mimura K, Teh JL, Okayama H, Shiraishi K, Kua LF, Koh V et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer science. 2018; 109:43-53
  42. Padmanabhan S, Gaire B, Zou Y, Uddin MM, Vancurova I IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling. Cell Signal. 2022; 97:9
  43. Chen B, Hu J, Hu X, Chen H, Bao R, Zhou Y et al. DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion. Nat Commun. 2022; 13:022-29754
  44. Xu P, Xiong W, Lin Y, Fan L, Pan H, Li Y Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression. Cell Death Dis. 2021; 12:021-04047
  45. Liu F, Liu J, Zhang J, Shi J, Gui L, Xu G Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer. Cancer Biol Ther. 2020; 21:963-971
  46. Nakagawa S, Serada S, Kakubari R, Hiramatsu K, Sugase T, Matsuzaki S et al. Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1. Mol Cancer Ther. 2018; 17:1941-1950
Iranian Journal of Immunology
Volume 20, Issue 3
September 2023
Pages 335-347
Files
Share
How to cite
Statistics